From Avi Roy. I like Avi Roy’s images he’s creating… and some good summaries:
After 20 years and 54 compounds tested across 30,000+ mice,
NIA 's Interventions Testing Program (ITP) published its most important finding. It’s not about which drug won. It’s about who it works for. Rapamycin + acarbose: 34% median lifespan increase in males. 28% in females. The largest effect the program has ever recorded. Better than either drug alone. But here’s the pattern nobody’s discussing: 12 of 13 life-extending compounds in the ITP worked primarily in males. Rapamycin is the single exception. The only longevity compound that works better in females. We’ve spent two decades testing longevity drugs in both sexes. The answer was staring back the whole time: longevity pharmacology has a sex problem.
Source: https://x.com/agingroy/status/2034279851318784317?s=20
